OR WAIT null SECS
- About Us
- Advertise
- Editorial Information
- Contact Us
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
Can FDA Reinvent Inspections?
Agnes Shanley is senior editor of Pharmaceutical Technology.
A plant inspection backlog caused by COVID-19 restrictions threatens innovation and public health. Now pressured to step up on-site inspections, will FDA embrace new methods?
Pressure is mounting on FDA to step up the pace of on-site inspections that were postponed due to COVID-19 safety issues and restrictions. An open question is whether the agency will use new remote auditing technologies to improve its ability to inspect facilities during the COVID-19 pandemic.
Read this article in BioPharm International's Regulatory Sourcebook March 2021 eBook.
Article details
BioPharm International
eBook: Regulatory Sourcebook, March 2021
March 2021
Pages: 4–5
Citation
When referring to this article, please cite it as: A. Shanley, "Can FDA Reinvent Inspections, BioPharm International Regulatory Sourcebook eBook (March 2021).
Related Content: